It is estimated only 2%–3% of adult cancer patients participate in clinical trials(1). Historically, women, racial/ethnic minorities, and economically-disadvantaged adults have been underrepresented in clinical trials. Factors that contribute to this disparity include the unavailability of clinical trials at treating sites, financial strains due to increased visits, social barriers (i.e., transportation and childcare), lack of knowledge (of clinical trials) among physicians, and lack of awareness among patients. (2)
Access to and participation in clinical trials ensures patients are offered cutting-edge therapies that aim to improve the prevention, diagnosis, and treatment of cancer. The BRIDGE program facilitates world-class care to residents of Brooklyn and Queens who are faced with a blood cancer diagnosis by mitigating barriers that may prevent them from enrolling or staying on a clinical trial.
Financial Support
The program provides financial support to offset excess costs for participating in clinical trials.
Patient Navigation
Patient navigators are specifically trained to assist patients with their treatment decisions, as well as educating patients on the benefits of clinical trials as a critical treatment option.
Decision Navigation Intervention
A decision aid administered by our patient navigators that empowers cancer patients to prepare for and actively participate in medical consultations and treatment decision appointments after a positive biopsy or laboratory study confirming a cancer diagnosis
At Brooklyn Methodist Hospital:
Here is a list of available studies at our sites for patients who have been diagnosed with a blood cancer:
Lymphoma
1. SKYGLO for Untreated B-Cell Lymphoma
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab in Combination With Pola-R-CHP Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080
2. ZanuVen for Untreated Chronic Lymphocytic Leukemia (CLL)
Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab consolidation in patients with minimal residual disease positivity
NCT05650723
3. LEO for Newly Diagnosed Non-Hodgkin Lymphoma
Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Protocol
NCT02736357